Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022

Rhea-AI Summary

Kamada Ltd. (NASDAQ: KMDA) will announce its financial results for Q1 2022 on May 17, before U.S. markets open. The company, known for its specialty plasma-derived therapeutics, will conduct a conference call at 8:30 AM ET on the same day to discuss the results. Interested parties can join the call or access it via a live webcast. Kamada’s portfolio includes FDA-approved products like GLASSIA® and KEDRAB®, along with recently acquired plasma-derived hyperimmune products. The company aims to leverage its development pipeline and manufacturing capabilities to drive growth.

Positive

• Diverse portfolio of FDA-approved products including GLASSIA® and KEDRAB®.
• Recent acquisition of plasma-derived hyperimmune products enhances product offerings.
• Strong focus on profitable growth from commercial activities and development expertise.

Negative

• None.

REHOVOT, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the first quarter ended March 31, 2022, prior to the open of the U.S. financial markets on Tuesday, May 17, 2022.

Kamada management will host an investment community conference call on Tuesday, May 17, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1 809-406-247 (from Israel), or 1-201-689-8263 (International) and entering the conference identification number: 13729770. The call will also be webcast live on the Internet at:
https://viavid.webcasts.com/starthere.jsp?ei=1547283&tp_key=3051633ddd

The call will also be archived for 90 days on the Company’s website at www.kamada.com.

About Kamada
Kamada Ltd. (the “Company”) is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company’s strategy is focused on driving profitable growth from our current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical market. The Company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. The Company has additional four plasma-derived products which are registered in markets outside the U.S. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has a diverse portfolio of development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added eleven biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2028. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

What date will Kamada Ltd. release its Q1 2022 financial results?

Kamada Ltd. will release its Q1 2022 financial results on May 17, 2022.

What is the time of the conference call for Kamada's Q1 results?

The conference call for Kamada's Q1 results will be at 8:30 AM Eastern Time on May 17, 2022.

How can I participate in Kamada Ltd.'s conference call?

You can participate by calling 1-877-407-0792 from the U.S., 1-809-406-247 from Israel, or 1-201-689-8263 internationally.

What products does Kamada Ltd. offer?

Kamada Ltd. offers FDA-approved products such as GLASSIA® and KEDRAB®, as well as recently acquired plasma-derived hyperimmune products.